{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:07:00Z","timestamp":1745899620448,"version":"3.40.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005897","name":"French Society of Dermatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Randomized controlled trials (RCTs) evaluating new systemic treatments for atopic dermatitis (AD) have increased dramatically over the last decade. These trials often incorporate topical therapies either as permitted concomitant or rescue treatments. Differential use of these topicals postrandomization introduces potential bias as they may nullify or exaggerate treatment responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the proportion of RCTs that clearly report the allowance or prohibition of concomitant and rescue topical treatments; and to examine the reporting of specific key parameters for these topicals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included RCTs of systemic AD medication included in a recent living systematic review. Inclusion criteria were published RCTs evaluating systemic immunomodulatory treatments in AD. Only anti-inflammatory topical therapies were included treatments in this review; emollients were not considered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We screened 83 AD trials and included 67 RCTs published between 1991 and 2023. The majority adequately reported the allowance or prohibition of concomitant topical treatments (n = 64\/67; 96%), but this clarity was less prevalent with regard to rescue topicals (n = 49\/67; 73%). All trials that permitted concomitant treatments consistently reported the type, although details on potency (n = 31\/35; 89%), duration (n = 19\/35; 54%), application frequency (n = 12\/35; 34%) and quantity (n = 2\/35; 6%) were less frequently reported. Similarly, trials that allowed rescue treatments often specified the type (n = 31\/34; 91%) but provided limited information on potency (n = 18\/34; 53%), duration (n = 3\/34; 9%), application frequency (n = 2\/34; 6%) and quantity (n = 0\/34; 0%). Notably, only 24% (n = 8\/34) clearly reported the criteria for using rescue topical treatments, with the phrase \u2018at investigator\u2019s discretion\u2019 used in most cases (n = 21\/34; 62%). In the multivariable logistic regression analysis including impact factor, the journal\u2019s policy on adhering to CONSORT guidelines, publication year, funding, number of patients randomized and blinding status, only publication year (\u2265 2020) was associated with having better reporting for rescue topical treatments (adjusted odds ratio 9.55, 95% confidence interval 1.76\u201339.80).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While most clinical trials of systemic treatments in AD report concomitant topical treatments, reporting practices for rescue topicals are less consistent and inadequate. A standardized approach to reporting topical treatment in AD trials is needed to enhance transparency and interpretability.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf031","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:58:27Z","timestamp":1738256307000},"page":"818-825","source":"Crossref","is-referenced-by-count":0,"title":["Reporting of concomitant and rescue topical therapies in randomized controlled trials evaluating a systemic treatment in atopic dermatitis: a scoping review"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-6365","authenticated-orcid":false,"given":"Sophie","family":"Leducq","sequence":"first","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham , Nottingham ,","place":["UK"]},{"name":"Department of Dermatology, University Hospital of Tours , Tours ,","place":["France"]},{"name":"INSERM, SPHERE, U1246, Tours University, Nantes University , Tours ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-156X","authenticated-orcid":false,"given":"Wei Chern Gavin","family":"Fong","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"Kim\u00a0S","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham , Nottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025042813561702700_ljaf031-B1","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/jdv.18429","article-title":"European guideline (EuroGuiDerm) on atopic eczema \u2013 part II: non-systemic treatments and treatment recommendations for special AE patient populations","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813561702700_ljaf031-B2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): systematic review and network meta-\u00adanalysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813561702700_ljaf031-B3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813561702700_ljaf031-B4","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"9","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025042813561702700_ljaf031-B5","first-page":"2447","article-title":"Concomitant therapies as an outcome measure. Part 1: Drugs","volume":"32","author":"Gossec","year":"2005","journal-title":"J Rheumatol"},{"key":"2025042813561702700_ljaf031-B6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025042813561702700_ljaf031-B7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jclinepi.2020.05.027","article-title":"Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review","volume":"125","author":"Ster AM","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2025042813561702700_ljaf031-B8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025042813561702700_ljaf031-B9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025042813561702700_ljaf031-B10","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2025042813561702700_ljaf031-B11","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/sim.927","article-title":"Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation","volume":"20","author":"White","year":"2001","journal-title":"Stat Med"},{"key":"2025042813561702700_ljaf031-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-021-00639-y","article-title":"Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate-to-severe atopic dermatitis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2025042813561702700_ljaf031-B13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.semarthrit.2019.03.009","article-title":"Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions","volume":"49","author":"Iudici","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025042813561702700_ljaf031-B14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025042813561702700_ljaf031-B15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/acr.20139","article-title":"Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect","volume":"62","author":"Pagnoux","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025042813561702700_ljaf031-B16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/j.pain.0000000000001690","article-title":"Rescue and concomitant analgesics in placebo-controlled trials of pharmacotherapy for neuropathic pain and low back pain","volume":"161","author":"Gr\u00f8vle","year":"2020","journal-title":"Pain"},{"key":"2025042813561702700_ljaf031-B17","doi-asserted-by":"crossref","first-page":"e070146","DOI":"10.1136\/bmj-2022-070146","article-title":"Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands","volume":"378","author":"Cro","year":"2022","journal-title":"BMJ"},{"key":"2025042813561702700_ljaf031-B18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archderm.136.3.381","article-title":"How well are randomized controlled trials reported in the dermatology literature?","volume":"136","author":"Adetugbo","year":"2000","journal-title":"Arch Dermatol"},{"key":"2025042813561702700_ljaf031-B19","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"2025042813561702700_ljaf031-B20","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1002\/ski2.372","article-title":"Re-engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis \u2013 a mixed methods study","volume":"4","author":"Porter","year":"2024","journal-title":"Skin Health Dis"},{"key":"2025042813561702700_ljaf031-B21","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025042813561702700_ljaf031-B22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jdv.18881","article-title":"Estimands for atopic dermatitis clinical trials: expert opinion on the importance of intercurrent events","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813561702700_ljaf031-B23","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME Core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813561702700_ljaf031-B24","doi-asserted-by":"crossref","first-page":"e076316","DOI":"10.1136\/bmj-2023-076316","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"2025042813561702700_ljaf031-B25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02770903.2014.947430","article-title":"Measurement properties of an asthma symptom and rescue medication use diary","volume":"52","author":"Clark","year":"2015","journal-title":"J Asthma"},{"key":"2025042813561702700_ljaf031-B26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/bjd\/ljad163","article-title":"Evaluating the effect of weekly patient-reported symptom monitoring on trial outcomes: results of the Eczema Monitoring Online randomized controlled trial","volume":"189","author":"Baker","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025042813561702700_ljaf031-B27","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/bmj.39590.732037.47","article-title":"What is missing from descriptions of treatment in trials and reviews?","volume":"336","author":"Glasziou","year":"2008","journal-title":"BMJ"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf031\/61702707\/ljaf031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/818\/61702707\/ljaf031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/818\/61702707\/ljaf031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:56:29Z","timestamp":1745862989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/818\/7990831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf031","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,30]]}}}